论文部分内容阅读
目的探讨大剂量氨溴索治疗重度支气管哮喘急性发作的临床效果。方法选择该院2010年3月—2012年3月重度支气管哮喘患者共80例,上述患者均符合支气管哮喘诊断标准,均为急性发作患者,病程程度为重度。上述患者随机分为观察组和对照组。两组患者均给予重度支气管哮喘急性发作常规治疗,观察组同时给予大剂量氨溴索静脉滴注,连续应用7d。观察两组患者临床症状和体征消失时间及治疗前后肺功能改善情况。结果观察组患者患者临床症状和体征消失时间为(8.1±3.5)d;对照组患者患者临床症状和体征消失时间为(14.5±4.1)d;观察组患者临床症状和体征消失时间显著早于对照组,差异有统计学意义(P<0.05);观察组治疗后FEV1、FEV1/FVC、PEF分别与对照组治疗后比较,差异有统计学意义(P<0.05)。结论大剂量氨溴索治疗重度支气管哮喘急性发作辅助作用显著,能够缩短患者临床症状消失时间,提高治疗效果,值得借鉴。
Objective To investigate the clinical efficacy of high-dose ambroxol in the treatment of severe bronchial asthma. Methods A total of 80 patients with severe bronchial asthma were selected from March 2010 to March 2012 in our hospital. All of the above patients met the diagnostic criteria of bronchial asthma. All patients were acute exacerbations with severe degree of disease. The above patients were randomly divided into observation group and control group. Both groups were given conventional treatment of severe bronchial asthma attack, the observation group also given intravenous infusion of large doses of ambroxol, continuous application of 7d. The clinical symptoms and signs disappeared in two groups and the improvement of pulmonary function before and after treatment. Results The disappearance time of clinical symptoms and signs in the observation group was (8.1 ± 3.5) days. The clinical symptoms and signs disappeared in the control group (14.5 ± 4.1 days). The clinical symptoms and signs of the observation group disappeared significantly earlier than those in the control group (P <0.05). The FEV1, FEV1 / FVC and PEF in the observation group after treatment were significantly different from those in the control group after treatment (P <0.05). Conclusion High-dose ambroxol treatment of acute exacerbation of severe bronchial asthma significant role in patients with clinical symptoms can reduce the disappearance of time and improve the therapeutic effect, it is worth learning from.